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Abstract
Background: The detection of cytokeratin-19 (CK-19) mRNA-positive circulating tumor cells (CTC) before and/or
after adjuvant chemotherapy in patients with operable breast cancer is associated with poor clinical outcome.
Reliable prognostic markers for late disease relapse are not available. In this study we investigated the value of CTC
detection during the first five years of follow-up in predicting late disease relapse.
Methods: Blood was analyzed from 312 women with operable breast cancer who had not experienced disease
relapse during the first two years of follow-up. A real-time reverse transcriptase polymerase chain reaction (RT-PCR)
for CK-19 mRNA was used to detect CTC three months after the completion of adjuvant chemotherapy and every
six months thereafter for a follow-up period of five years.
Results: Eighty patients (25.6% of the study population) remained CTC free throughout the five-year period. A
change in CTC status was observed in 133 patients (42.6%); 64 patients (20.5%) with initially CK-19 mRNA-positive
CTC during the first 24 months turned CTC-negative afterwards while 69 (22.1%) who were initially CTC-negative
became CTC-positive. Ninety-nine patients (31.7%) remained persistently CK-19 mRNA-positive. After a median
follow-up period of 107 months (range: 38 to 161 months), the persistently CTC-positive patients with either
hormonal receptor positive or negative tumors, had a higher risk of late-disease relapse compared to the
persistently CTC-negative patients (36.4% versus 11.2%, P <0.001). Multivariate analysis revealed that persistently
CTC-positive patients also had a shorter disease-free (P = 0.001) and overall survival (P = 0.001).
Conclusions: Persistent detection of CK-19 mRNA-positive CTC during the first five years of follow-up is associated
with an increased risk of late relapse and death in patients with operable breast cancer and indicates the presence
of chemo-and hormonotherapy-resistant residual disease. This prognostic evaluation may be useful when deciding
on subsequent adjuvant systemic therapy.
Introduction
Invasive breast cancer is the most common malignancy
in women, accounting for 28 percent of new cancer
cases and 15 percent of cancer deaths [1]. Due to
declining mortality rates that are attributable mostly to
the use of screening mammography and effective
adjuvant therapy, more women nowadays survive their
breast cancer [2]. Since metastatic disease is considered
incurable, the early recognition and treatment of poten-
tially still curable minimal residual disease is one of the
major goals of care of breast cancer survivors and
requires the in-depth understanding of relapse patterns.
Depending on the specific breast cancer type, the
majority of recurrences occur during years 2 to 5 [3],
although they can occur earlier or much later [4,5].
Especially for women with hormone receptor-positive
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disease, more than one-half of all recurrences and
deaths occur beyond five years from diagnosis [5,6]. To
date no tool is available for monitoring the effect of
adjuvant treatment and in most cases the recurrence
risk is calculated based on previous statistical analyses
[7]. Therefore, with existing methods, prediction of the
risk of relapse for the individual patient is limited.
Disseminated tumor cells (DTC) in bone marrow [8,9]
and circulating tumor cells (CTC) in peripheral blood
[10,11] of patients with operable breast cancer have
been shown to be independent adverse prognostic fac-
tors for disease recurrence and disease-related death.
Immunocytochemistry using antibodies against proteins
that are expressed on epithelial but not on mesenchymal
cells is widely used for the detection of DTC and CTC.
However, the detection of mRNA transcripts for specific
epithelial markers by using reverse transcriptase poly-
merase chain reaction (RT-PCR) and, more recently, the
quantitative real-time RT-PCR (QPCR) seems to have
higher diagnostic sensitivity [12]. The major advantage
of RNA-based approaches is related to the rapid degra-
dation of RNA released from cells in the blood by
RNAses; therefore, the origin of detectable blood RNA
transcripts is considered to be viable cells. Cytokeratin-
19 (CK-19), a cytoskeletal component present in normal
and cancerous epithelial cells, has been extensively used
for the detection of breast cancer cells in mesenchymal
tissues and seems to be the most sensitive and reliable
tumor marker in both patients with operable and meta-
static breast cancer [13,14].
Several studies have shown the prognostic significance
of CK-19 mRNA-positive CTC in patients with operable
breast cancer [10,11,15-17]. However, all these studies
have investigated the prognostic value of CTC at the
time of initial diagnosis and before the initiation and/or
following the completion of adjuvant chemotherapy.
Only a few reports exist concerning the clinical rele-
vance of DTC, but none for CTC, during the surveil-
lance period after the completion of adjuvant
chemotherapy [18,19]. The unfavorable clinical outcome
of patients with detectable isolated tumor cells in bone
marrow was shown in the latter studies [18,19]. Given
that DTC and CTC are theoretically the primary targets
of adjuvant treatment, their fate after systemic therapy
could be a potential useful marker permitting a direct
and individualized assessment of treatment efficacy and
a more accurate estimation of the risk of relapse.
In the present study, we sought to evaluate the clinical
relevance of CK-19 mRNA-positive CTC detected by a
QRT-PCR assay at different time points during the fol-
low up period after the completion of adjuvant che-
motherapy in patients with operable breast cancer. We
hypothesized that patients presenting detectable CK-19
mRNA-positive CTC during follow-up despite the
administration of adjuvant therapy, could be at an
increased risk of late disease relapse (defined as relapse
at least two years after the end of adjuvant chemother-
apy) and death.
Materials and methods
Patients and clinical samples
We conducted a retrospective analysis of prospectively
collected data in the context of an ongoing longitudinal
study that has been previously reported [17]. Women
with operable breast cancer (stage I to III) who were
under surveillance and had not experienced disease
relapse during the first two years of follow-up, were eli-
gible for this study. All patients had received adjuvant
chemotherapy mostly in the context of research proto-
cols of the Hellenic Oncology Research Group. After
completion of adjuvant chemotherapy, patients received
adjuvant radiotherapy and hormonal therapy when indi-
cated according to their individual disease characteris-
tics. There were no subgroups of patients who received
only adjuvant hormone therapy or no adjuvant systemic
therapy at all.
Patients’ follow-up consisted of pertinent medical his-
tory and physical examination, with laboratory and ima-
ging studies restricted as indicated, every three months
for the first two years, every six months for the next
three years and yearly thereafter. All treating physicians
were completely unaware of the CK-19 mRNA results
for their individual patients and all follow-up laboratory
and imaging studies to detect disease relapse were per-
formed independently of the CK-19 mRNA results. All
patients signed an informed consent to participate in
the study, which was approved by the Ethics and Scien-
tific Committees of our institution.
Cytokeratin-19 mRNA-positive CTC were monitored
at specific time points after the completion of adjuvant
chemotherapy for a five-year follow-up period. The first
blood sample was obtained three months after the end
of chemotherapy and subsequent samples were obtained
every six months thereafter during the five-year follow-
up.
Patients were classified into four groups based on
their CTC status during the first two years and the sub-
sequent three years of follow-up (as persistently nega-
tive, persistently-positive, negative turn to positive and
the opposite). At least one CK-19 mRNA-positive blood
sample in the corresponding period of time was
required for classifying the patient in the CTC-positive
group. On the other hand, if all the collected blood sam-
ples were negative for CK-19 mRNA, the patient was
characterized as CTC-negative. Using this definition, the
patients were classified in the “persistently CTC-nega-
tive” group, if there were no positive blood samples for
CK-19 mRNA throughout the five-year follow-up
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period. On the other hand, the “persistently CTC-posi-
tive” patients had at least one positive blood sample for
CK-19 mRNA in the first two years and at least another
positive one in the subsequent three years of follow-up.
Accordingly, patients in the “CTC-negative turn to posi-
tive” group had no positive samples in the first two
years, but at least one positive sample in the next three
years. The opposite was true for the “CTC-positive turn
to negative” group.
Blood samples and real-time RT-PCR for CK-19 mRNA
Twenty milliliters (mL) of peripheral blood in EDTA
were collected at each visit. To avoid contamination with
epithelial skin cells, all blood samples were obtained at
the middle of vein puncture after the first 5 mL of blood
was discarded. Peripheral blood mononuclear cells were
obtained by gradient density centrifugation using Ficoll-
Hypaque [10]. Total RNA isolation was carried out with
the use of Trizol LS reagent (Gibco, Life Sciences, BRL,
Grand Island, NY, USA) according to the manufacturer’s
instructions. The isolated RNA was dissolved in diethyl-
pyrocarbonate-treated water and stored at -80°C until
used. RNA concentration was determined by absorbance
reading at 260 nm with the Hitachi UV-VIS (U-2000)
spectophotometer (Tokyo, Japan). The integrity was
tested by PCR amplification of the b-actin housekeeping
gene. As positive and negative controls we used RNA
samples prepared from the MCF-7 breast cancer and
ARH-77 leukemic cell lines respectively.
Reverse transcription of RNA was carried out with the
Thermoscript RT-PCR system (Invitrogen, Paisley, UK).
Complementary DNA (cDNA) was synthesized accord-
ing to the manufacturer’s instructions. The QPCR assays
for the detection of CK-19 mRNA-positive cells, the pri-
mers and the details of the cycling protocol have been
previously described [20]. Briefly, 2 μl of cDNA were
placed into an 8 μl reaction volume containing 1 μl of
the sense primer CK-19-for (3 mM), 1 μl of the anti-
sense primer CK-19-do (3 mM), 2.4 μl of the LightCy-
cler Fast Start DNA Master Hybridization Probes
reagent (10 × concentration), 1 μl of the probe CK-19-
FL (3 mM) and 1 μl of the probe CK-19-LC (3 mM)
[15]. The quality of cDNAs was evaluated by real-time
PCR for the housekeeping gene glyceraldehyde-3-phos-
phate dehydrogenase.
The presence of more than 0.6 MCF-7 cell equiva-
lents/5 μg of total RNA was considered a positive result,
according to the previously reported analytic detection
limit of our assay [20]. Using this cutoff, only 2 of 89
(2.2%) female healthy blood donors were positive for
CK-19 mRNA-positive cells while none of 9 women
with benign breast disease (fibroadenomas) had positive
blood samples [20]. The high specificity of the method
was made possible by avoiding contamination of skin
epithelial cells during venipuncture, as well as by care-
fully designing the primers and hybridization probes.
Hence, amplification of the known CK-19 pseudogenes
and genomic DNA was avoided [20].
Statistical analysis
Disease-free survival (DFS), defined as the time from
study entry until the day of the first evidence of disease
recurrence, and overall survival (OS), defined as the
time from study entry to death, were the main depen-
dent variables of the study. The data-cut-off date was 20
July 2010. Kaplan-Meier curves for DFS and OS were
compared using the log-rank test to provide a univariate
assessment of the prognostic value of selected clinical
risk factors. Clinicopathologic factors known to be asso-
ciated with prognosis, such as menopausal status (pre-
menopausal vs postmenopausal), tumor size (T1 vs T2-
3), number of the involved axillary lymph nodes (0 to 3
vs ≥ 4), histological grade (1 or 2 vs 3), estrogen recep-
tor (ER) status (negative vs positive), progesterone
receptor (PR) status (negative vs positive) and HER-2/
neu status (negative vs positive) were tested in univariate
analysis. Variables that were found to be significant at
the univariate screen were then entered in a stepwise
multivariate Cox proportional hazards regression model
to identify those with independent prognostic informa-
tion. Entry into and removal from the model were set at
5% and 10%, respectively. All statistical tests were per-
formed at the 5% level of significance. SPSS version 13
(SPSS Inc, Chicago, IL, USA) statistical software was
used for the analysis. This report is written according to
the reporting recommendations for tumor marker prog-
nostic studies (REMARK criteria) [21].
Results
Patients’ characteristics
A total of 455 consecutive patients with diagnosis of
operable breast cancer treated and followed at the
Department of Medical Oncology of the University Hos-
pital of Heraklion between January 1997 and December
2004 were screened for eligibility for this study. A total
of 412 (91%) patients belong to the same cohort that
was used to evaluate the prognostic significance of CK-
19 mRNA-positive CTC detection before initiation and/
or after completion of adjuvant chemotherapy [17].
A total of 143 patients were excluded for reasons
listed in Figure 1 and 312 were included in the study.
Patients’ characteristics at the time of primary diagnosis
in relation to CTCs status during follow-up are sum-
marized in Table 1. The persistent detection of CTC
during follow-up did not correlate with the patient’s
and/or tumor’s characteristics, such as age (p = 0.197),
menopausal status (p = 0.372), tumor size (p = 0.637),
lymph node status (p = 0.082), histopathological grade
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(p = 0.746) and hormone receptor status (p = 0.156).
There was a difference in the type of adjuvant che-
motherapy administered, with more patients in the per-
sistently positive group having received anthracycline-
based regimens (p = 0.011).
Detection of CK-19 mRNA-positive cells during follow-up
Cytokeratin-19 mRNA-positive cells were detected in
the blood of 232 patients (74.4%) at any time point dur-
ing the five-year follow-up period, while 80 patients
(25.6%) remained CTC-free throughout the same period
455 consecutive patients with operable breast cancer 
were screened for study eligibility 
312 patients were eligible 
143 were excluded:
42 had an early disease relapse  
44 did not have CTC assessed at any 
time 
15 did not have CTC assessed during 
follow up years: 0-2 
41 did not have CTC assessed during 
follow up years: 3-5 
1 had advanced stage disease 
1st & 2nd year 






























Figure 1 Study enrollment, reasons for patients’ exclusion and patients’ classification according to CK-19 mRNA CTC status.
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(persistently negative). More specifically, 99 patients
(31.7%) had persistently detectable CK-19 mRNA-posi-
tive cells both during the first two and the subsequent
three years of follow-up (persistently-positive group). A
change in CK-19 mRNA status was observed in almost
half of patients (133 patients or 42.6%). Of those, 64
patients (20.5%) with initially detectable CK-19 mRNA-
positive cells during the first 24 months turned CTC-
Table 1 Patients’ characteristics at diagnosis according to CK-19 mRNA-positive cells during follow-up
Characteristics All Patients CK-19 mRNA-persistently negative CK-19 mRNA-persistently positive
N % N % N %
Patients enrolled 312 80 25.6 99 31.7
Age Mann-Whitney
P = 0.197
median (range) 54 (26 to 77) 51.5 (26 to 75) 54 (28 to 75)
Menopausal status P = 0.372
Pre-menopausal 145 46.5 41 51.3 44 44.4
Post-menopausal 167 53.5 39 48.8 55 55.6
Tumor size T2/T3 vs T1
T1 116 37.2 30 37.5 33 33.3 P = 0.637
T2 174 55.8 43 53.8 59 59.6
T3 22 7.1 7 8.8 7 7.1
Lymph nodes P = 0.082
N0 107 34.3 33 41.3 28 28.3
N1 to 3 119 38.1 29 36.3 35 35.4
N > 3 86 27.6 18 22.5 36 36.4
Histology grade P = 0.746
1/2 159 51.0 39 48.8 56 56.6
3 119 38.1 28 35.0 36 36.4
lobular 34 10.9 13 16.3 7 7.1
HR P = 0.156
ER(-)/PR(-) 70 22.4 24 30.0 22 22.2
Other 190 60.9 39 48.8 60 60.6
Unknown 52 16.7 17 21.3 17 17.2
HR and Her-2 P = 0.116
ER(-)/PR(-)/HER-2(-) 52 16.7 19 23.8 16 16.2
Other 255 65.1 41 51.3 66 66.7
Unknowm 57 18.3 20 25.0 17 17.2
Radiation therapy P = 0.937
No 24 7.7 7 8.8 9 9.1
Yes 289 92.3 73 91.2 90 90.9
Hormonotherapy P = 0.103
No 23 7.4 10 12.5 5 5.1
Yes 289 92.6 70 87.5 94 94.9
Type of hormonotherapy P = 0.119
No hormonotherapy 23 7.4 10 12.5 5 5.1
AIs 33 10.6 10 12.5 11 11.1
T 50 16.0 10 12.5 19 19.2
AIs & T 57 18.3 9 11.3 22 22.2
LHRH 32 10.3 11 13.8 8 8.1
LHRH + T or AIs 117 37.5 30 37.5 34 34.3
Chemotherapy P = 0.011
CMF 30 9.6 11 13.8 4 4.0
FEC 149 47.8 31 38.8 57 57.6
T/EC 133 42.6 38 47.5 38 38.4
AIs, aromatase inhibitors; CMF, cyclophosphamide-methotraxate-fluorouracil; FEC, fluorouracil-epirubicin-cyclophosphamide; HR, hormone receptor; LHRH,
luteinizing-hormone-releasing hormone; T, tamoxifen; T/EC, taxane/epirubicin-cyclophosphamide.
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negative afterwards (positive turn to negative group),
while 69 patients (22.1%) who were initially CTC-nega-
tive became CTC-positive afterwards (negative turn to
positive group) (Figure 1).
Detection of CK-19 mRNA-positive cells and clinical
outcome
Disease recurrence
After a median follow-up period of 107 months (range:
38 to 161 months), 63 patients (20.2%) had developed a
distant (n = 56; 88.8%) or locoregional disease recur-
rence (n = 7; 11.2%) (Table 2). Compared to the persis-
tently negative patients, only the group of CK-19
mRNA-persistently positive patients had a significant
higher risk of disease relapse (36.4% versus 11.2%; Fish-
er’s exact test, p < 0.001). In fact, risk of disease recur-
rence was the highest in patients with persistently-
positive CTC (36.4% versus 7.8%; p < 0.001 and 36.4%
versus 18.8%; p = 0.016 compared to a positive turn to
negative and a negative turn to positive group, respec-
tively) (Table 2).
The five-year DFS rates were 82.5% versus 92.7% for
persistently-positive versus persistently-negative
patients, respectively. As illustrated in Figure 2A, per-
sistently positive patients had a significantly shorter
DFS than the persistently negative patients (p < 0.001).
Although no group has as yet reached the median
DFS, there was a progressive decrease in the DFS of
the four groups of patients according to the detection
of CK-19 mRNA-positive CTC during the five years of
follow-up (Figure 2A).
Survival
Forty-one patients (13.1%) died during follow-up as a
result of disease progression. Twenty-four (58.5%) and
five (12.2%) of these deaths occurred in the persistently-
positive and persistently-negative group, respectively
(Fisher’s exact test; p = 0.001; Table 2). The 10-year
overall survival rates were 81.4% for persistently-positive
versus 96.7% for persistently-negative patients. Estimated
median overall survival was significantly shorter for per-
sistently positive compared to persistently negative
patients (p = 0.013). Similar to DFS, there was a pro-
gressive decrease in the OS rates of the four groups of
patients according to the detection of CK-19 mRNA-
positive CTC during the five years of follow up (Figure
2B).
Subgroup analysis based on cumulative number of
positive tests for pre-chemotherapy CTC status and
hormone receptors
Since patients underwent serial blood draws for the
assessment of CK-19 mRNA-positive CTC, we analyzed
our data to address the question whether the cumulative
number of positive tests matters. Among patients with
positive tests, 38.7% (during the first two years of fol-
low-up), 24.4% (during the subsequent three years) and
57.3% (during all the five years) had two or more posi-
tive test results (Additional file 1, Supplementary Table
S1). No difference was found in the disease-free survival
between the groups with different cumulative number of
positive tests, probably due to the small number of
patients and events in each group (Additional file 1:
Supplementary Figure S1).
Given the prognostic role of the CTC detection before
the administration of adjuvant chemotherapy [11], we
investigated whether it could offer additional prognostic
information to that of the serial measurements of CTC
during follow-up. For this purpose, we reviewed the pre-
chemotherapy CTC status of the patients included in
this analysis (Additional file 1: Supplementary Table S2).
No difference was found in the detection rate of the
CK-19 mRNA-positive CTC between the four groups
(Pearson chi-square, p = 0.320). Interestingly, the persis-
tently positive patients with detectable CK-19 mRNA-
positive CTC before the administration of adjuvant che-
motherapy had shorter DFS but not OS compared to
Table 2 Incidence of disease recurrence and deaths according to the detection of CK-19 mRNA-positive circulating
tumor cells









Fisher’s Exact test, P
Persistently Positive 99 36 (36.4) 63 (63.6) P < 0.001 24 (24.2) 75 (75.8) P = 0.001
Persistently Negative 80 9 (11.2) 71 (88.8) 5(6.3) 75 (93.8)
Positive Turn to negative 64 5 (7.8) 59 (92.2) P < 0.001
versus persistently positive
3 (4.7) 61 (95.3) P = 0.001
versus persistently positive
Negative Turn to positive 69 13 (18.8) 56 (81.2) P = 0.016
versus persistently positive
9 (13.0) 60 (87.0) P = 0.079
versus persistently positive
While also,
P = .248 for relapse of turn to positive versus persistently negative
P = .172 for deaths of turn to positive versus persistently negative
CK-19, cytokeratine-19.
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the patients of the same group who tested negative for
pre-chemotherapy CK-19 mRNA-positive CTC (Addi-
tional file 1: Supplementary Figure S2).
Finally, a subgroup analysis was performed according
to hormone receptor status. Interestingly, the persis-
tently positive patients with either hormone receptor
positive or negative tumors had a significantly higher
relapse rate (Table 3), risk of death and shorter DFS
than the persistently negative patients [(p = 0.039 and p
= 0.004 for persistently positive vs persistently negative
patients with ER/PR negative and ER and/or PR positive
tumors respectively) (Figure 3a, 3b)]. However, the over-
all survival was shorter only for the persistently positive
patients with ER/PR negative tumors (p = 0.035, Figures
3c, 3d).
Univariate and multivariate analysis
Persistent detection of CK-19 mRNA-positive CTC dur-
ing the follow-up after the completion of adjuvant che-
motherapy, tumor size greater than 2.0 cm, more than
three involved axillary lymph nodes and postmenopausal
status were significantly associated with reduced DFS
and OS in the univariate analysis (Table 4). Multivariate
analysis revealed that persistent detection of CK-19
mRNA-positive CTC, tumor size and more than three
involved axillary lymph nodes were independent prog-
nostic factors for shorter DFS and OS (Table 5).
Discussion
We provide, to our knowledge, the first clear evidence
of a strong correlation between detection of CK-19
mRNA-positive CTC during follow-up and increased
risk of late disease relapse and death in patients with
either hormonal receptor positive or negative operable
breast cancer. These findings support the role of CTC
monitoring as an adjunct to standard clinical and radio-
graphic methods in the evaluation of disease status dur-
ing follow-up.
Although the prognostic role of DTC for disease
relapse and death in early breast cancer is clearly docu-
mented [8], the assessment of tumor cells in peripheral
blood is easier, more broadly applicable than bone mar-
row aspirates and certainly more appropriate for
repeated testing. Our group has previously reported that
the detection of CK-19 mRNA-positive CTC in the
blood of patients with node-negative operable breast
cancer before the initiation of any systemic treatment
was an independent prognostic factor associated with an
increased risk of disease recurrence [11]. More recently,
we demonstrated that the risk of relapse could be distin-
guished based on the response of their CTC to adjuvant
chemotherapy [17] and we reviewed our experience
regarding the prognostic role of CK-19 positive CTC in
operable breast cancer [22]. Other investigators have
shown that longitudinal monitoring of CTC was
Figure 2 (A): Disease-free and (B): Overall Survival according to CTC detection during follow-up.
Table 3 Incidence of Disease recurrence and deaths according to CTC detection and hormonal receptor status









Fisher’s Exact test, P
ER(-)/PR(-) Persistently Positive 22 9 (40.1) 13(59.9) P = 0.044 8 (34.4) 16 (63.6) P = 0.009
Persistently Negative 24 3 (12.5) 21 (87.5) 1(4.1) 24 (95.9)
ER(+) and/or PR(+) Persistently Positive 60 26 (43.3) 34 (46.7) P < 0.001 15 (25) 45 (75) P = 0.007
Persistently Negative 39 4 (10.2) 35 (89.2) 2 (5.1) 37 (94.9)
CK-19, cytokeratine-19; HR, hormonal receptor; ER, estrogens receptor; PR, progesterone receptor.
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superior to a single test analysis, and a more than 10-
fold increase in the CTC numbers towards the end of
therapy is highly predictive for early relapse [23].
The present study was designed to investigate the
prognostic value of CTC detection during follow-up in
predicting the risk of late disease relapse. Accordingly,
patients who experienced disease relapse during the first
two years from diagnosis were excluded from this analy-
sis and the median follow-up period was extended to
107 months. The changes in CK-19 mRNA-positive
CTC status were thus analyzed in 312 patients and four
groups were distinguished. The first group included
patients without detectable CTC throughout the follow-
up period, only 11.2% of whom experienced disease
relapse. The second group included patients with CK-19
mRNA-positive CTC during the first two years. These
patients had similar relapse risk to the persistently nega-
tive patients and might indeed have derived a benefit
from the adjuvant therapy. In the third group patients
with detectable CTC after, but not during, the first two
years were included. The relapse risk for these patients
was almost 50% higher compared to the risk of persis-
tently negative patients, presumably due to the growth
of therapy-resistant residual disease, which could not be
detected early on by our method. Finally, in the fourth
group patients with CK-19 mRNA-positive CTC
throughout the follow-up period were included. One
third of them experienced disease relapse, while one out
of four patients died. This persistently positive group
was by far the group with the highest relapse risk.
Almost 40% of the “positive at any time” patients had
detectable CK-19 mRNA-positive CTC only in one single
sample. This observation could theoretically be attributed
at least in part to false positive results. However, given
the very low false positive rate of our assay (approxi-
mately 2%) this occurrence should be rather limited.
Our results could be explained by the hypothesis that
drug-resistant cancer cell clones generated during tumor
evolution, constitute the re-emerging dominant tumor
cell population and may start proliferating under the
selective pressure of drug exposure. The high probability
of subsequent disease relapse indicates that these resis-
tant cells have a proliferative and survival advantage.
This hypothesis seems to be supported by the observa-
tion (unpublished data) that the vast majority of CTC
detected during the follow-up period from CK-19
mRNA persistently positive patients who had experi-
enced disease relapse, did not express the M30 antigen
which is a neo-epitope expressed only after caspase clea-
vage of cytokeratin 18 during early apoptosis [24,25].
Figure 3 Disease-free and overall survival according to the CTC detection and hormone receptor status during follwow-up.
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An algorithm for the optimal timing of CTC detection
during follow-up is currently lacking. Our findings sug-
gest that serial assessments every six months for up to
five years represent an acceptable timetable. Further-
more, for hormone receptor positive patients, in whom
half of the recurrences occur beyond the five years,
extension of the CTC serial assessments for even longer
might be reasonable. These patients may represent the
group which could derive benefit from an extended
adjuvant treatment approach or switch to another agent.
The QRT-PCR used in our study is not the only avail-
able assay for CTCs’ detection. A semi-automated
approach, the CellSearch® system (Veridex Raritan, NJ,
USA), which has been approved by the Food and Drug
Administration for monitoring CTC in the metastatic
breast cancer setting, has gained considerable attention
[26,27]. The prognostic relevance of CTC detection in
the peripheral blood of operable breast cancer patients,
using the CellSearch® system, has been evaluated in the
SUCCESS trial. According to the most updated results,
Table 4 Univariate analysis (unadjusted relative risks) for disease-free and overall survival
DFS Overall survival
HR 95% CI P-value HR 95% CI P-value
Menopausal status 1.075 to 3.064 1.027 to 3.836
Post vs Pre 1.815 0.026 1.985 0.041
Tumor status 1.304 to 4.419 1.710 to 11.114
T2/T3 vs T1 2.401 0.005 4.359 0.002
Nodes 1.418 to 3.832 1.527 to 5.207
N> 3 vs N0-3 2.331 0.001 2.819 0.001
Histology grade 0.989 to 2.805 0.644 to 2.390
3 vs 1/2 1.665 0.055 1.240 0.520
HR 0.454 to 1.504 0.585 to 2.387
ER(-)/PR(-) vs other 0.826 0.533 1.182 0.641
Triple negative 0.454 to 1.681 0.492 to 2.348
ER(-)/PR(-)/HER-2 vs Other 0.874 0.686 1.075 0.856
Hormonotherapy 0.696 to 3.759 0.442 to 4.687
No vs Yes 1.618 0.264 1.439 0.546
Chemotherapy CMF (ref) 0.589 to 3.812 0.352 to 2.976
FEC 0.339 0.911
T/EC 1.498 0.389 to 2.745 0.396 1.024 0.388 to 3.564 0.966
1.034 0.947 1.176 0.775

























CK-19, cytokeratine-19; CMF, Cyclophosphamide-Methotraxate-Fluorouracil; DFS, disease-free survival; FEC, Fluorouracil-Epirubicin-Cyclophosphamide; HR,
hormone receptor; T/EC, Taxane/Epirubicin-Cyclophosphamide.
Table 5 Prognostic factors by multivariate analysis for disease-free and overall survival
DFS Overall survival
HR 95% CI P-value HR 95% CI P-value
Menopausal status
Post vs Pre
1.462 0.858 to 2.492 0.163 1.365 0.794 to 2.347 0.260
Tumor status
T2/T3 vs T1
2.187 1.167 to 4.098 0.015 2.135 1.141 to 3.994 0.018
Nodes
N> 3 vs N0-3
1.801 1.080 to 3.003 0.024 2.150 1.109 to 4.168 0.023

























CK-19, cytokeratine-19; CMF, cyclophosphamide-methotraxate-fluorouracil; DFS, disease-free survival; ER, estrogen receptor; FEC, fluorouracil-epirubicin-
cyclophosphamide; PR, progesteron receptor; T/EC, taxane/epirubicin-cyclophosphamide.
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detection of at least one CTC in 23 mL of peripheral
blood after surgical resection of the primary tumor and
before the start of adjuvant systemic treatment was an
independent predictor for worse DFS and OS in multi-
variate analysis [28]. The prognostic significance of CTC
detection before and/or after the completion of adjuvant
chemotherapy [17], as well as the high specificity/sensi-
tivity represent some advantages of the QPCR assay
compared to the CellSearch®. On the other hand, the
ability for direct enumeration, morphological analysis
and isolation of CTC for further analysis are important
advantages of the latter [29].
Our study has some potential limitations that should
be taken into account when considering the results.
This is a single institution study and the analysis was
performed in one laboratory. Therefore, before the
establishment of our assay as a clinically relevant test,
sample analysis must be performed in several labora-
tories and stability during shipment must be demon-
strated. Also and despite the fact that our assay has
been validated in multiple cohorts and data analyses
[10,11,14,15,17], neither survival advantage, nor
improvement in quality of life has been demonstrated in
a prospective randomized trial. In this regard, the
SWOG and the Breast Cancer Intergroup of North
America have initiated a prospective trial in the meta-
static setting to test whether patients with elevated CTC
count (using the CellSearch® system) after one cycle of
first-line chemotherapy will benefit from a switch to a
different chemotherapeutic regimen (SWOG protocol
S0500). However, for patients with operable breast can-
cer the lower CTC detection rate post-chemotherapy
makes this strategy far more challenging [28,30].
Additionally, the patients in our study received var-
ious types of adjuvant therapy based on available clini-
cal and disease data at the time of enrolment. This
heterogeneity may be a confounding variable, but the
similarity between our findings on relapses (20.2%) and
those published by the Early Breast Cancer Trialists’
Collaborative Group is encouraging [6]. Finally, the
cellular heterogeneity of CTCs was not analysed using
the QRT-PCR detection method. This is very impor-
tant since various studies have already confirmed that
CTC present significant genetic and phenotypic het-
erogeneity [31], which could explain why not all
patients who have detectable CTC experience disease
relapse, while some patients relapse although they do
not present detectable CTC.
Conclusions
Our data support a prognostic role and potential clini-
cal utility of monitoring CTC in conjunction with stan-
dard surveillance strategies for the follow-up of
patients with operable breast cancer. Given their
independent unfavorable prognostic value for reduced
DFS and OS, the detection of CTC after therapy could
be considered as indirect evidence for the presence of
chemotherapy and hormonal therapy resistant disease.
Analyzing a 20-mL blood sample at various time
points during follow-up might, therefore, enable clini-
cians to assess the efficacy of administered adjuvant
therapy, limit patient exposure to ineffective agents
with unnecessary toxicity, assist in the identification of
patients who are most likely to benefit from clinical
trials of novel therapeutics and perhaps make eradica-
tion of cancer cells more feasible, when the tumor bur-
den is still low and before the appearance of clinically
overt metastases. Since only one-third of patients with
persistent CK-19 mRNA-positive CTC experience dis-
ease relapse, additional prognostic markers are needed
to define better those patients who indeed might bene-
fit from novel extended adjuvant therapies. These
hypotheses can be addressed only in the context of
well-designed, adequately powered, prospective, rando-
mized clinical studies. In this way, definitive proof will
be provided as to whether monitoring of the CTC can
be used to improve clinical outcome in patients with
operable breast cancer.
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